Actively Recruiting
Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
Led by Sunnybrook Health Sciences Centre · Updated on 2025-09-09
144
Participants Needed
1
Research Sites
274 weeks
Total Duration
On this page
Sponsors
S
Sunnybrook Health Sciences Centre
Lead Sponsor
P
Prostate Cure Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Prostate Stereotactic ablative body radiotherapy (SABR) is an established technique that delivers radiation in a non-invasive approach for men with prostate cancer. The treatment regimen is given in total of 5 fractions with one treatment per day at every other day or weekly sessions. Ultra-hypofractionated radiotherapy (UHRT) is an emerging monotherapy for localized prostate cancer however, several trials have observed demonstrating superior biochemical control of a two-fraction (HDR) over single-fraction approach. The study aims to compare an experimental shorter course of prostate ultra-hypofractionated radiotherapy (UHRT) that will deliver what is expected to be an equivalent amount of radiation as given in the standard 5 treatment regimen. UHRT is given in 2 treatments with one treatment a week for 2 consecutive weeks.
CONDITIONS
Official Title
Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed prostate adenocarcinoma (centrally reviewed)
- Low or favorable intermediate risk disease meeting one of the following: low risk (T1-T2b, grade group 1, and PSA < 10 ng/ml) or favorable risk with either one intermediate risk factor (cT2c, grade group 2, or PSA 10-20 ng/ml) or grade group 3 with PSA < 20, less than cT2c, and less than 10% pattern 4/5
You will not qualify if you...
- Androgen deprivation therapy (LHRH-agonists or antiandrogens) given or planned
- Prior pelvic radiotherapy
- Anticoagulation medication if unsafe to stop for gold seed insertion
- Diagnosis of bleeding diathesis
- Large prostate (>90cm3) on imaging
- Use of immunosuppressive medications
- Inflammatory bowel disease
- Presence of dual hip prostheses
- Contraindications to having MRI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5
Actively Recruiting
Research Team
D
Danny Vesprini, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here